Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1983; 1:355-364
© 1983 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krikler, D.
Right arrow Articles by Rowland, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krikler, D.
Right arrow Articles by Rowland, E

Clinical value of calcium antagonists in treatment of cardiovascular disorders

DM Krikler and E Rowland

All calcium antagonists have the ability to decrease the symptoms and signs in some patients with ischemic heart disease and help lower the blood pressure in hypertensive persons, but in clinical doses nifedipine does not exhibit antiarrhythmic properties, although these are an important part of the action of verapamil, diltiazem and some substances with a similar chemical structure. In certain disorders beta-adrenergic blocking drugs are useful adjuncts, and under some circumstances, particularly variant angina and supraventricular arrhythmias, specific calcium antagonists are the drugs of choice. More data are needed to define the role of calcium antagonists during cardiopulmonary bypass, in the protection of the ischemic myocardium, in the management of hypertrophic cardiomyopathy and in specific cases of primary pulmonary hypertension. When used with an appropriate sense of perspective and careful observation, calcium antagonists provide useful additional means of helping selected patients suffering from particular cardiovascular diseases.


This article has been cited by other articles:


Home page
Arch Intern MedHome page
J. P. Nicholson, L. M. Resnick, and J. H. Laragh
Hydrochlorothiazide Is Not Additive to Verapamil in Treating Essential Hypertension
Arch Intern Med, January 1, 1989; 149(1): 125 - 128.
[Abstract] [PDF]


Home page
JAMAHome page
S. P. Van Camp and R. A. Peterson
Cardiovascular Complications of Outpatient Cardiac Rehabilitation Programs
JAMA, September 5, 1986; 256(9): 1160 - 1163.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement